Diabetes and insulin Shots or pens

Product Details:

Semaglutide is a GLP-1 analogue with 94% sequence as same as to human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP-1 receptor. Semaglutide reduces blood glucose in a glucose dependent manner by simulating insulin secretion and lowering glucagon secretion when blood glucose is high. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying. During hypoglycemia, Semaglutide diminishes insulin secretion and does not impair glucagon secretion. Semaglutide reduces body weight and body fat mass by an overall reduced appetite.

Product Details:

Semaglutide injection (Ozempic) is used along with a diet and exercise program to control blood sugar levels in adults with type 2 diabetes (condition in which the body does not use insulin normally and therefore cannot control the amount of sugar in the blood) when other medications did not control the sugar levels 

Product Details:

Semaglutide 2.4 mg is a GLP-1 receptor agonist, with 94% similarity to naturally occurring human GLP-1 hormone. It induces weight loss by reducing hunger, increasing feeling of fullness and thereby helping people eat less and reduce their calorie intake.

Product Details:

Ozempic  (semaglutide) injection 0.5 mg, 1 mg, or 2 mg is an injectable prescription medicine used: along with diet and exercise to improve blood sugar in adults with type 2 diabetes. to reduce the risk of major cardiovascular events such as heart attack, stroke, or death in adults with type 2 diabetes with known heart disease.

Product Details:

Semaglutide is a GLP-1 analogue with 94% sequence as same as human GLP-1. Semaglutide acts as a GLP-1 receptor agonist that selectively binds to and activates the GLP- receptor. GLP-1 is a physiological regulator of appetite and caloric intake. It is also present in several areas of brain that involved in appetite regulation. Semaglutide lowers body weight through decreased calorie intake and by an overall reduced appetite. It also stimulates insulin secretion and reduces glucagon secretion in a glucose dependent manner.

Product Details:

Fitaro is a glucagon-like peptide 1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus and established cardiovascular disease.

Product Details:

Semaglutide reduces blood glucose in a glucose dependent manner by simulating insulin secretion and lowering glucagon secretion when blood glucose is high. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying

Product Details:

Semaglutide reduces blood glucose in a glucose dependent manner by simulating insulin secretion and lowering glucagon secretion when blood glucose is high. The mechanism of blood glucose lowering also involves a minor delay in gastric emptying. During hypoglycemia, Semaglutide diminishes insulin secretion and does not impair glucagon secretion. Semaglutide reduces body weight and body fat mass by an overall reduced appetite.

Product Details:

Humalog 100IU/ml Kwikpen is a fast-acting insulin, starts working within 10-20 minutes after injection. It works similar to insulin produced by the body. Insulin facilitates reuptake of sugar in muscle and fat cells and also suppresses the production of sugar in the liver.